📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Expedited Program Requests (TILA-278)

Document ID: DESIG-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): FDA/EMA expedited

Expedited Program Requests — TILA-278

Evaluation and, where supported, requests for expedited programs for TILA-278 in Ulcerative Colitis (moderate-to-severe) (Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review; EU PRIME/accelerated assessment; orphan designation as applicable), with the qualifying rationale.

TILA-278 is a humanized IgG1 bispecific monoclonal antibody that simultaneously antagonizes TL1A (TNFSF15) and agonizes the IL-22 receptor (IL-22R), administered subcutaneously and produced from a Chinese hamster ovary (CHO) cell culture process with Protein A capture followed by polishing chromatography. The molecule is intended to treat adults with moderate-to-severe Ulcerative Colitis (UC). This document sets out the Sponsor's (Virtual Biopharma Inc.) assessment of each expedited pathway against its statutory/regulatory criteria, the qualifying rationale drawn from the completed Phase 2b study TILA278-201, and the planned regulatory interactions through which each request will be filed. The assessment reflects the product's dual, mechanistically complementary mode of action: TL1A antagonism to attenuate mucosal inflammation and fibrostenotic remodeling, coupled with IL-22R agonism to promote epithelial restitution and mucosal healing.

Serious condition and unmet medical need

Moderate-to-severe UC is a serious, chronic, immune-mediated disease associated with substantial morbidity, including disabling symptoms (rectal bleeding, urgency, high stool frequency), recurrent hospitalization, corticosteroid dependence, risk of colectomy, and an elevated long-term risk of colorectal neoplasia. It therefore meets the "serious condition" threshold common to all of the expedited pathways evaluated below.

Despite the availability of multiple advanced therapies (anti-TNF agents, anti-integrin therapy, IL-12/23 and IL-23 inhibitors, JAK inhibitors, and S1P receptor modulators), an unmet medical need persists: a meaningful proportion of patients fail to achieve corticosteroid-free clinical and endoscopic remission, primary non-response and secondary loss of response are common, and durable mucosal healing remains difficult to attain—particularly in patients previously exposed to, or refractory to, advanced therapy. No currently approved UC therapy pairs immunologic antagonism of a fibrosis-relevant cytokine (TL1A) with direct epithelial-reparative signaling (IL-22R agonism) in a single molecule. This mechanistic differentiation, together with the reparative and anti-fibrotic components of the mechanism, is central to the unmet-need rationale supporting the expedited requests below.

Summary of supporting clinical evidence (TILA278-201)

Study TILA278-201 was a Phase 2b, randomized, double-blind, placebo-controlled, 1:1:1 study evaluating a 12-week induction course of subcutaneous TILA-278 (High dose, Low dose, or placebo) in adults with moderate-to-severe UC. Of 1700 patients screened, 900 were randomized (299 High / 300 Low / 301 Placebo), and the Full Analysis Set (FAS) comprised 840 patients (284 High / 283 Low / 273 Placebo).

The primary endpoint, clinical remission at Week 12 (modified Mayo score ≤ 2 with no individual subscore > 1), was met with a dose-ordered, placebo-separated effect: 37.3% (106/284) for High dose, 16.2% (46/283) for Low dose, and 0.7% (2/273) for placebo. Key secondary endpoints were concordant. The least-squares mean change from baseline in modified Mayo score was −3.36 (High), −2.76 (Low), and −1.00 (placebo), corresponding to placebo-adjusted differences of −2.36 (High) and −1.77 (Low). Endoscopic improvement was achieved in 48.9%, 27.9%, and 6.2% of the High, Low, and placebo groups, respectively.

The magnitude of separation from placebo on both a symptom/composite endpoint (clinical remission) and an objective endpoint (endoscopic improvement), the internal dose-response consistency, and the mechanistic plausibility of the reparative/anti-fibrotic effect together constitute the preliminary clinical evidence relied upon in the requests below. These endpoints (clinical remission and endoscopic improvement) are recognized measures capable of supporting traditional (regular) approval in UC, a point that bears directly on the Accelerated Approval assessment.

FDA Fast Track designation

Assessment: To be requested. Fast Track is available for a drug intended to treat a serious condition where nonclinical or clinical data demonstrate the potential to address an unmet medical need. Moderate-to-severe UC satisfies the seriousness criterion, and the TILA278-201 results—supported by the differentiated dual mechanism—demonstrate the potential to address unmet need beyond currently available therapies. The Sponsor intends to request Fast Track designation, supported by the totality of TILA278-201 and the nonclinical package, in conjunction with the active IND.

The principal benefits sought are more frequent and earlier interaction with the review division on development and trial design, eligibility for Accelerated Approval and Priority Review if the relevant criteria are subsequently met, and—critically for program timelines—the ability to submit portions of the Biologics License Application (BLA) for Rolling Review. Because a therapeutic monoclonal antibody of this class does not warrant genotoxicity, carcinogenicity, or dedicated cardiac (hERG/thorough-QT) studies, the nonclinical timeline is not expected to gate an expedited clinical program, which strengthens the feasibility of Rolling Review.

FDA Breakthrough Therapy designation

Assessment: To be requested (post End-of-Phase-2). Breakthrough Therapy designation (BTD) is available for a drug intended to treat a serious condition where preliminary clinical evidence indicates the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints. The TILA278-201 data provide the preliminary clinical evidence: clinical remission of 37.3% (High) versus 0.7% (placebo) and endoscopic improvement of 48.9% (High) versus 6.2% (placebo), each on a clinically significant endpoint, with an internally consistent dose response.

The "substantial improvement over available therapy" standard requires contextualization beyond a placebo comparison; the Sponsor's rationale rests on (i) the magnitude of the observed treatment effect, (ii) the first-in-class dual mechanism combining TL1A antagonism with IL-22R–driven epithelial repair, and (iii) the potential relevance of this mechanism to advanced-therapy–experienced and refractory patients who represent the core of the unmet need. The benefits sought include all Fast Track features plus intensive, cross-disciplinary guidance on an efficient development program and organizational commitment from senior FDA managers. The Sponsor plans to submit the BTD request in connection with the End-of-Phase-2 (Type B) meeting, once the confirmatory Phase 3 induction and maintenance program is defined.

FDA Accelerated Approval

Assessment: Not the primary pathway; retained for consideration. Accelerated Approval permits approval based on a surrogate endpoint reasonably likely to predict clinical benefit, or on an intermediate clinical endpoint, for a serious condition offering meaningful advantage over available therapy. In UC, the endpoints already used in TILA278-201—clinical remission by modified Mayo score and endoscopic improvement—are generally accepted to support traditional (regular) approval when demonstrated in adequate and well-controlled induction and maintenance studies. Accordingly, the Sponsor does not currently anticipate that Accelerated Approval will be required for the primary indication, as the planned confirmatory program is designed to support regular approval directly.

The Sponsor will nonetheless keep Accelerated Approval under consideration for any future development in a population or context (for example, structural/anti-fibrotic outcomes attributable to TL1A antagonism) where a surrogate or intermediate clinical endpoint may be the most efficient basis for early access, and will discuss any such approach with the review division before adoption.

FDA Priority Review

Assessment: To be requested at BLA submission. Priority Review is a review-clock designation, requested at the time of the marketing application and determined by FDA at filing, for an application that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition. The Sponsor intends to request Priority Review with the BLA, which will be filed under 21 CFR Part 601, on the basis of the efficacy magnitude and mechanistic differentiation summarized above and the accompanying safety and immunogenicity (anti-drug antibody) characterization. Priority Review would target a shortened review goal relative to standard review.

EU PRIME (PRIority MEdicines)

Assessment: To be requested. PRIME is the EMA's scheme for early and enhanced support of medicines that address an unmet medical need, based on early clinical evidence of the potential to bring a major therapeutic advantage. The Phase 2b proof-of-efficacy from TILA278-201—robust placebo separation on clinical remission and endoscopic improvement with a coherent dose response—provides a suitable evidentiary basis for a PRIME request by an established (non-SME) developer. The benefits sought include appointment of a CHMP/rapporteur contact point, a kick-off meeting with a multidisciplinary group, enhanced and structured scientific advice, and confirmation of eligibility for accelerated assessment at the time of the Marketing Authorisation Application (MAA). The Sponsor plans to submit the PRIME eligibility request supported by the TILA278-201 dataset.

EU accelerated assessment

Assessment: To be requested at MAA submission. Accelerated assessment reduces the CHMP review timeframe for products expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The dual TL1A-antagonist / IL-22R-agonist mechanism and the reparative/anti-fibrotic rationale support a claim of therapeutic innovation. The Sponsor will request accelerated assessment at MAA submission, ideally as a continuation of PRIME support, and will confirm eligibility with the (Co-)Rapporteurs in advance.

Orphan designation

Assessment: Not applicable. Moderate-to-severe UC is a prevalent condition whose patient population exceeds the orphan prevalence and population thresholds in both the United States and the European Union. Orphan designation is therefore not sought for this indication. Should any future narrowly defined subpopulation meet the applicable orphan criteria, the Sponsor would assess designation separately at that time.

Regulatory interaction and submission strategy

The requests above will be sequenced through the Sponsor's planned regulatory interactions: an End-of-Phase-2 (Type B) meeting with FDA to align on the confirmatory Phase 3 induction and maintenance design and to submit the Breakthrough Therapy request; corresponding EMA Scientific Advice and the PRIME eligibility request; and, at the marketing-application stage, requests for Priority Review (US) and accelerated assessment (EU). Where Fast Track and/or Breakthrough Therapy are granted, the Sponsor intends to use Rolling Review to submit completed BLA sections as they become available.

Expedited timelines compress Chemistry, Manufacturing and Controls (CMC) and nonclinical development, and the strategy accounts for this. For this CHO-derived bispecific antibody, the CMC program will be advanced in parallel with the accelerated clinical plan, addressing viral safety and adventitious-agent control per ICH Q5A(R2), cell-substrate and cell-banking characterization per ICH Q5D, stability per ICH Q5C, and specification-setting and analytical characterization per ICH Q6B, with manufacturing comparability across process changes managed under ICH Q5E. The nonclinical package follows ICH S6(R1), with the cynomolgus monkey as the sole pharmacologically relevant species and pharmacokinetics characterized under target-mediated drug disposition, together with immunogenicity/anti-drug antibody assessment. Consistent with established principles for therapeutic monoclonal antibodies, genotoxicity, carcinogenicity, and dedicated cardiac electrophysiology (hERG / thorough-QT) studies are not warranted and are not planned; the absence of these study requirements reduces the risk that nonclinical activities become rate-limiting under an expedited timeline. The Sponsor will confirm the acceptability of the accelerated CMC and nonclinical strategy with each Agency as part of the interactions described above.